Overview of Opioid Abuse in United States and Its Governance's Interventions

Abstract

Abstract: Objective This article is mainly about the profile and challenge of opioid abuse in the US and also introduce the targeted intervention strategies of the government and the health institutions of US in recent years. Methods By consulting domestic and foreign documents and accessing to the official website of the US government and the health institutions, information of opioid abuse was retrieved. Results and Conclusion Through the efforts of the US government, the US Food and Drug Administration, the US Drug Enforcement Administration and the US Centers for Disease Control and Prevention, significant contribution was made to the reduction of opioid abuse in the United States, but they still face many challenges.

Key words: United States, opioid, drug abuse, intervention, strategy

CLC Number:

R951

YANG , Yu-hui , XU Xiu-li ,ZHU Zhu. Overview of Opioid Abuse in United States and Its Governance's Interventions[J]. Chinese Journal of Pharmacovigilance, 2017, 14(12): 746-751.

References

[1] CDC. Opioid prescribing is still high and varies widely throughout the U.S[EB/OL]. (2017-07-06)[2017-08-22]. https://www.cdc.gov/media/releases/2017/p0706-opioid.html.
[2] Havens Jennifer R,Lofwall Michelle R,Frost Simon D W, et al. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users[J]. Am J Public Health, 2013, 103(1): e44-52.
[3] Matthew Miller MD MPH ScD, Til Stürmer MD MPH, Azrael D, et al. Opioid Analgesics and the Risk of Fractures in Older Adults with Arthritis[J]. Journal of the American Geriatrics Society, 2011, 59(3):430.
[4] Creanga A A, Sabel J C, Ko J Y, et al. Maternal drug use and its effect on neonates: a population-based study in Washington State[J]. Obstetrics & Gynecology, 2012, 119(5):924.
[5] FDA. Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse andAbuse[EB/OL].(2017-08-20)[2017-08-23].https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm338566.htm.
[6] Rudd R A, Seth P, David F, et al. Increases in Drug and Opioid-Involved Overdose Deaths-United States, 2010-2015[J]. Mmwr Morbidity & Mortality Weekly Report, 2016, 65(5051):1445.
[7] CDC.Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2017[EB/OL]. (2017-06-27)[2017-08-23]. https://wonder.cdc.gov.
[8] Florence C S, Zhou C, Luo F, et al. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013[J]. Medical Care, 2016, 54(10):901.
[9] Centers for Disease Control and Prevention(CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008[J]. MMWR Morb. Mortal. Wkly. Rep., 2011, 60(43): 1487-1492.
[10] University of Wisconsin Pain & Policy Studies Group. Global Opioid Consumption, 2015[EB/OL].(2015)[2017-08-23]http://www.painpolicy.wisc.edu/global.
[11] 邹武捷，满春霞，杨淑苹，等. 麻醉药品和精神药品管制研究Ⅱ-美国管制物质的管制历程与现状[J]. 中国药房, 2017, 28(1):10-14.
[12] DEA. Title 21 United States Code (USC) Controlled Substances Act[EB/OL].(2017-07-17)[2017-08-23].https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html.
[13] DEA. DEA proposes reduction to amount of controlled substances to be manufactured in 2018[EB/OL].(2017-08-04)[2017-08-22].https://www.dea.gov/divisions/hq/2017/hq080417.shtml.
[14] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2013[J].Federal Register,2013,78(152):48193-48197.
[15] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2014[J]. Federal Register,2014,79(164):50700-50704.
[16] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2015[J]. Federal Register，2015;80(179):55642-55646.
[17] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2016[J]. Federal Register，2016,81(206):73421-73426.
[18] DEA. Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine,
and Phenylpropanolamine for 2017[J]. Federal Register，2017,82(149):36449-36453.
[19] DEA. Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropan-olamine for 2018[J]. Federal Register，2017,82(150):36830-36834.
[20] CDC. OpioidPrescribing[EB/OL]. (2017-07-06)[2017-08-22]. https://www.cdc.gov/vitalsigns/opioids/index.html.
[21] CDC. New data show continuing opioid epidemic in the United States.[EB/OL](2016-12-16)[2017-08-23].https://www.cdc.gov/media/releases/2016/p1216-continuing-opioid-epidemic.html.
[22] CDC. CDC awards $12 million to help states fight opioid overdose epidemic[EB/OL]. (2017-07-17)[2017-08-23]. https://www.cdc.gov/media/releases/2017/p0717-opioid-funding.html.
[23] BBC. Trump urged to declare national emergency over opioid crisis[EB/OL]. (2017-08-01) [2017-08-23]. http://www.bbc.com/news/world-us-canada-40793540.
[24] FDA. FDA Perspective on AbuseDeterrent Opioid Development. [EB/OL]. (2017-03-07) [2017-08-23].https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm545923.pdf.
[25] 李淑芳, 潘文灏. 美国FDA基于品种的药品风险管理计划研究与制定[J]. 中国药物警戒, 2013, 10(3):144-147.
[26] FDA. Abuse-Deterrent Opioids-Evaluation and Labeling Guidance for Industry[EB/OL]. [2017-08-24].https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf.
[27] FDA.General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry[EB/OL].[2017-08-24]. https://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM492172. pdf.
[28] FDA强化阿片类药物标签的警告信息[J].上海医药, 2013,(19):62-62.
[29] FDA. New Safety Measures Announced for Immediate Release (IR) Opioids[EB/OL].(2016-03-22)[2017-08-24].https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm491437.htm.
[30] FDA. Califf, FDA top officials call for sweeping review of agency opioids policies[EB/OL]. (2016-02-04)[2017-08-24].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm484765.htm.
[31] FDA. FDA requests removal of Opana ER for risks related to abuse[EB/OL].(2017-06-8)[2017-08-24].https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm562401.htm.
[32] Califf Robert M,Woodcock Janet,Ostroff Stephen. A Proactive Response to Prescription Opioid Abuse[J].N. Engl. J. Med., 2016, 374(15): 1480-1485.
[33] DEA.DEA's Community Outreach Section[EB/OL]. [2017-08-24].https://www.dea.gov/prevention/overview.shtml.
[34] DEA.DEA Releases New Rules That Create Convenient But Safe and Secure Prescription Drug Disposal Options[EB/OL]. (2014-09-08)[2017-09-01]. https://www.dea.gov/divisions/hq/2014/hq090814.shtml.
[35] DEA. DEA Brings in Record Amount of Unused Prescription Drugs on National Prescription Take Back Day[EB/OL]. (2017-03-08)[2017-08-25]. https://www.dea.gov/divisions/hq/2017/hq050817a.shtml.
[36] DEA. Working Together to Break the Cycle of Drug Tracking, Drug Violence, and Drug Abuse[EB/OL]. (2017-02) [2017-08-25]. https://www.dea.gov/prevention/360-strategy/360_Fact_Sheet.pdf.
[37] DEA. To Combat Today's Opioid Crisis, DEA and Discovery Education Launch Powerful New Middle and High School Education Program Operation Prevention[EB/OL]. (2016-10-25)[2017-08-25]. https://www.dea.gov/divisions/hq/2016/hq102516.shtml.
[38] DEA. DRUG PREVENTION PUBLICATIONS[EB/OL]. [2017-08-24]. https://www.dea.gov/pr/publications.shtml.
[39] CDC. Our History-Our Story[EB/OL]. (2016-04-26)[2017-08-25]. https://www.cdc.gov/about/history/index.html.
[40] CDC. About the Morbidity and Mortality Weekly Report (MMWR) Series[EB/OL]. (2017-06-16)[2017-08-25]. https://www.cdc.gov/mmwr/about.html.
[41] CDC. Guideline Resources[EB/OL]. (2017-08-31)[2017-09-01]. https://www.cdc.gov/drugoverdose/prescribing/resources.html.
[42] Dowell D, Haegerich T M, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain-United States,V2016[J]. Jama, 2016, 315(15):1624-1645.
[43] CDC. What States Need to Know about PDMPs[EB/OL]. (2017-08-28)[2017-09-01].https://www.cdc.gov/drugoverdose/pdmp/states.html.